A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:
Back to home » Top Stories » IAS 2009
IAC 2008 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
Cape Town, South Africa
July 19-22, 2009

Chronic Stress and Non-AIDS Diseases—Is There a Link?

July 27, 2009

By Tim Horn

Chronic stress may increase the risk of non-AIDS, age-related health problems in people living with HIV, according to a team of Spanish researchers presenting intriguing new data at the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention on Tuesday, July 21, in Cape Town.

High blood levels of certain inflammatory chemicals called cytokines—notably interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFa)—have been associated with a spectrum of age-related conditions including cardiovascular disease, osteoporosis, type 2 diabetes and certain cancers.

Higher-than-normal levels of these cytokines have been documented in people living with HIV, as have high rates of early onset age-related diseases. While most research conducted to date has focused on the potential roles of HIV and antiretroviral (ARV) therapy on these abnormalities, another known risk factor may be involved: chronic psychological stress.

Stress has been linked to increased IL-6 and TNFa in studies involving HIV-negative individuals. In turn, Carmina Fumaz, MA, of the Germans Trias i Pujol Hospital in Barcelona and her colleagues hypothesized that stressed-out HIV-positive people may also be more likely to have elevated levels of inflammatory cytokines and, therefore, a greater risk of age-related manifestations.

To explore this possibility, Fumaz’s group evaluated 21 HIV-positive individuals with undetectable viral loads for at least 12 months while on antiretroviral therapy, all with CD4 counts that never fell below 200 cells. Blood levels of IL-6 and TNFa were measured, as were each individual’s stress level, using the standardized Perceived Stress Scale (PSS).

Study volunteers averaged 40 years of age. Eighty-one percent were men, and the average CD4 count upon entering the study was 564 cells.

Forty-seven percent of the participants had evidence of chronic stress, with an average PSS score of 15.5; a score above 14 was considered evidence of chronic stress.

Patients with stress had significantly higher average levels of IL-6 (13 picograms/milliliter) and TNFa (5.1 pg/mL) when compared with subjects without chronic stress (IL-6: 1.1 pg/mL; TNFa: 2.4 pg/mL). These differences between the two groups were statistically significant, meaning they were too great to have occurred by chance.

Among the individuals with chronic stress, Fumaz’s group pointed out, IL-6 levels averaged more than six times the level of 2.5pg/mL, a well-defined cutoff associated with accelerated decline of physical function.

“The impact of chronic stress on the premature appearance of aging-related pathologies through immune dysregulation merits further research,” the authors concluded in their published abstract.

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 1 (of 1 total)    

Gary, Nashville, 2009-07-29 09:33:56
WOW this article is speaking directly to the last 8 months of my life my stress levels had changed and since then I have had age related illness due to non HIV my CD4 is right there at 568 and I'm undetectable but I have auto immune type I diabetes found I have had a mild heart attack and other problems there is actual fact to this study and I would love to see more put to the fact and FYI I guess we shouldn't stress so much (LOL) stay healthy and rest.

comments 1 - 1 (of 1 total)    

Funding for coverage of this conference is provided, in part, by an unrestricted educational grant from Tibotec Therapeutics, a division of Ortho Biotech Products, LP.
More from IAS 2009

Starting and Switching Treatment

July 31, 2009
South African Study: Nurses Comparable to Doctors in Monitoring HIV Management
July 30, 2009
Acyclovir Slows HIV Disease Progression, But Fails to Reduce HIV Transmission
July 27, 2009
Switch From Norvir-Boosted to Unboosted Reyataz Safe and Effective
July 24, 2009
Kaletra Is Better Than Viramune for Kids Exposed to Viramune at Birth
Study Hints That Micronutrient Supplement Might Help HIV-Positive Kids
A Quad NRTI Regimen Fails to Perform
July 23, 2009
HIV Treatment Effective Without Laboratory Monitoring in Southern Africa Study
Viramune Has Similar Efficacy to Reyataz
July 22, 2009
Pediatric Viramune May Still Work as Treatment in Kids Exposed at Birth
Triple-Drug Regimen Works Well for Heavily Treatment-Experienced Patients
Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment
People on Sustiva Have Less Risk for Treatment Failure Than People on Kaletra
Substantial Single-Year Gains in ARV Access in 2008
July 21, 2009
Isentress Going Strong After Three Years in Treatment Starters
More Than Half Could Need Treatment Within 2 Years of Infection
July 20, 2009
Pediatric HIV: Successes and Challenges
GRACE Shows Similar Treatment Response Rates in Women and Men on Prezista Treatment
CD4 Counts Key to AIDS-Free Survival While on HIV Treatment

Women and HIV

July 28, 2009
Menopause May Occur Earlier in HIV-Positive Women
July 24, 2009
No Transmission and Few Birth Defects in Babies Born to African Mothers on HIV Treatment
July 22, 2009
Mma Bana: Lowest-Ever Mother-to-Child HIV Transmission Rates With Combo Therapy in Botswana
July 20, 2009
GRACE Shows Similar Treatment Response Rates in Women and Men on Prezista Treatment

HIV/AIDS Complications

August 3, 2009
New Studies Question Abacavir Role in Heart Attack Risk
July 30, 2009
Perhaps More Lipodystrophy With Sustiva?
July 29, 2009
High Prevalence of Vitamin D Deficiency in HIV-Positive Men
July 28, 2009
Menopause May Occur Earlier in HIV-Positive Women
July 27, 2009
Chronic Stress and Non-AIDS Diseases—Is There a Link?
July 23, 2009
Zinc Supplements Prevent Immune Decline in Chronic Substance Users
Efavirenz, Race Linked to Vitamin D Deficiency
Cancer Rates Are Lower, but Still Present at Higher CD4 Levels
More Than Half of People With HIV Might Have Cognitive Impairment
July 22, 2009
ARV Therapy of Little Benefit in Preventing Anal Cancer
ARV Treatment Eases Cape Town TB Rates
July 21, 2009
ARV Treatment Protects Against Malaria in Ugandan Study

Experimental HIV Drugs

July 28, 2009
Once- vs. Twice-Daily Kaletra for Treatment Veterans
July 27, 2009
Two Studies Explore Switch to Boosted Prezista Monotherapy
July 22, 2009
Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment
July 21, 2009
Selzentry Comparable to Sustiva After 96 Weeks in Treatment Naives
Shionogi-GSK Integrase Inhibitor Shows Promise

HIV Transmission and Prevention

July 30, 2009
Acyclovir Slows HIV Disease Progression, But Fails to Reduce HIV Transmission
July 24, 2009
No Transmission and Few Birth Defects in Babies Born to African Mothers on HIV Treatment
July 22, 2009
Mma Bana: Lowest-Ever Mother-to-Child HIV Transmission Rates With Combo Therapy in Botswana
July 21, 2009
Circumcision Protects Insertive MSM Partners

Global HIV/AIDS

July 21, 2009
ARV Treatment Protects Against Malaria in Ugandan Study


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.